Principal Financial Group Inc. Has $6.44 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. trimmed its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 24.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 577,727 shares of the biopharmaceutical company's stock after selling 184,961 shares during the quarter. Principal Financial Group Inc. owned approximately 0.44% of Dynavax Technologies worth $6,436,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company's stock valued at $116,682,000 after acquiring an additional 126,458 shares during the last quarter. Kynam Capital Management LP grew its position in shares of Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company's stock valued at $52,616,000 after buying an additional 2,725,397 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock valued at $27,830,000 after buying an additional 53,600 shares during the period. Great Point Partners LLC raised its position in shares of Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock worth $26,660,000 after acquiring an additional 1,109,080 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Dynavax Technologies in the second quarter worth approximately $17,615,000. Institutional investors and hedge funds own 96.96% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on DVAX shares. The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a "neutral" rating on the stock in a research report on Thursday, August 8th. HC Wainwright restated a "buy" rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Up 1.5 %

Shares of DVAX stock traded up $0.18 on Thursday, reaching $12.35. 659,117 shares of the company were exchanged, compared to its average volume of 2,163,617. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The company has a 50-day moving average of $11.45 and a 200-day moving average of $11.31. The company has a market cap of $1.62 billion, a price-to-earnings ratio of 93.62 and a beta of 1.34. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.01.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.